From: Cardiac complications in patients with COVID-19: a systematic review
Myocarditis | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Authors | Age (years) all patients | Age (years) treatment group | Age (years) control group | Sex M/F+ | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | N° pts o cases-controls with myocarditis | Troponin T or I value -BNP or NT-proBNP valueπ | LVEDV – EF (n° pts or cases-controls)π | Inotropes and corticosteroids | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
Deng et al. [19] | 65 (49–70.8)§ | 68 (57–77)§ | 56 (39–67)§ | 57/55 | Hypertension (36) Diabetes (19) Coronary heart disease (15) Atrial fibrillation (4) | COPD (4) | Severe patients if: Respiratory distress and RR> 30 acts/min or SpO2 < 93% or P/F < 300 Critical patients if: Respiratory failure with mechanical ventilation or shock or multi-organ failure that require hospitalization in UTI | 13-1 | TnI > 0.12 ng/ml+ NT-proBNP 1142 ng/ml (388.3–5956.5)§ | NA | NA | Mechanical ventilation (28) ECMO (3) | Death (14) Discharge (37) |
Dweck et al. [24] | 62 (52–71)§ | 64 (53–73)§ | 60 (51–69)§ | 844/365 | Hypertension (445) Diabetes (233) Ischemic heart disease (167) Heart failure (113) Valvular disease (80) | NA | Patients in critical care setting (ICU, coronary care unit, emergency room, cardiac catheter laboratory) | 35 | NA | Low EF (21) | NA | NA | NA |
Doyen et al. [21] | 69+ | NA | NA | 1/0 | Hypertension (1) | NA | NA | 1 | TnI 9002 ng/L+ | Normal EF | Hydrocortisone | Mechanical ventilation (1) | Discharge (1) |
Hu et al. [26] | 37+ | NA | NA | 1/0 | NA | NA | NA | 1 | TnT > 10,000 ng/L+ BNP > 21,025 ng/L+ | LVEDV 58 mm+ EF 27% + | Milrinone Methylprednisolone Immunoglobulins | Pneumonia (1) Pleural effusion (1) | Discharge (1) |
Hussain et al. [28] | 51+ | NA | NA | 1/0 | Hypertension (1) | NA | NA | 1 | Tn 0.29 ng/ml+ BNP 1287 pg/ml+ | EF 20% | Dobutamine | ARDS (1) Mechanical ventilation (1) | Death (1) |
Inciardi et al. [29] | 52+ | NA | NA | 0/1 | NA | NA | NA | 1 | TnT 0.24 ng/ml+ NT-proBNP 5647 pg/ml+ | EF 35% | Dobutamine Methylprednisolone | Not reported | Hospitalized (1) |
Kim IC et al. [31] | 21+ | NA | NA | 0/1 | NA | NA | NA | 1 | TnI 1,26 ng/ml+ NT-proBNP 1929 pg/mL+ | Severe dysfunction EF | NA | NA | NA |
Kunal et al. [32] | 51.2 ± 17.7° | 60.9 ± 15.1° | 47.9 ± 17.4° | 70/38 | Hypertension (41) Diabetes (35) Cardiovascular disease (14) Dyslipidemia (6) Heart failure (1) | COPD (6) | NA | 3 | NA | NA | NA | Sepsis (25) ARDS (12) AKI (8) Diabetic ketoacidosis (3) Intracranial hemorrhage (1) | Death (1) Recovery (2) |
Monmeneu et al. [35] | 43+ | NA | NA | 1/0 | NA | NA | NA | 1 | TnT 29 ng/L+ NT-proBNP 456 pg/ml+ | EF 50–55% | Methylprednisolone | Pneumonia (1) Pleural effusion (1) | Discharge (1) |
Pascariello et al. [36] | 19+ | NA | NA | 1/0 | NA | Autistic spectrum disorder (1) | NA | 1 | TnT 1033 ng/L+ NT-proBNP 47,650 ng/L+ | LVEDV 56 mm+ EF 15–20%+ | Adrenaline Dexamethasone | Bilateral interstitial pneumonia (1) Mechanical ventilation (1) | Discharge (1) |
Paul et al. [37] | 35+ | NA | NA | 1/0 | NA | NA | NA | 1 | TnI 2885 ng/L | Normal EF | NA | NA | Discharge (1) |
Zeng et al. [55] | 63+ | NA | NA | 1/0 | Smoke (1) | Allergic cough (1) | NA | 1 | TnI 11.37 g/L+ NT-proBNP 22,600 pg/mL+ | LVEDV 61 mm+ EF 32%+ | Methylprednisolone Immunoglobulins | ARDS (1) CRRT (1) ECMO (1) Septic shock (1) | Death (1) |